Budesonide is better retained in airway tissue than fluticasone propionate and mometasone furoate due to the formation of lipophilic, slowly hydrolyzed budesonide esters Source: Eur Respir J 2003; 22: Suppl. 45, 281s Year: 2003
Budesonide is retained in the airways longer than mometasone furoate due to the reversible formation of lipophilic budesonide fatty acid esters - significance for asthma therapy Source: Eur Respir J 2002; 20: Suppl. 38, 53s Year: 2002
Fluticasone propionate is as potent but more receptor-selective than mometasone furoate Source: Eur Respir J 2001; 18: Suppl. 33, 95s Year: 2001
Higher cellular retention and activity after pulse exposure by budesonide (BUD) than fluticasone propionate (FP) and mometasone furoate (MF) Source: Eur Respir J 2001; 18: Suppl. 33, 158s Year: 2001
Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on human airway inflammation Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Mometasone furoate is a less specific glucocorticoid than fluticasone propionate Source: Eur Respir J 2002; 20: 1386-1392 Year: 2002
Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on neuronal inflammation and acetylcholine release Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
A comparison of fluticasone propionate (FP) and mometasone furoate (MF) nasal spray in the treatment of nasal polyposis associated with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006
Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Mometasone furoate delivered via Breezhaler and Twisthaler in patients with asthma Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019
Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Characterization of airflow properties of the mometasone furoate dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 102s Year: 2001
Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler(R) Source: Eur Respir J 2001; 17: 1332-1333 Year: 2001
Fluticasone furoate restores leptin/leptin receptor pathway in nasal epithelial cells Source: Annual Congress 2011 - Lung cell biology Year: 2011
Fluticasone furoate (FF): Prolonged duration of action compared with other ICS Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Source: Eur Respir J 2014; 43: 773-782 Year: 2014
Assessment of the defined daily dose for mometasone furoate dry powder inhaler in persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
The absolute bioavailability of fluticasone furoate (FF) and vilanterol (VI) trifenatate following inhaled administration in combination in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Dosage form proportionality, dose proportionality and pharmacokinetics (PK) of mometasone furoate (MF) and formoterol fumarate (F) from three combination MDI formulations Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008